Dr. Rotkowitz on BRAF/MEK Combination Side Effects

Michael Rotkowitz, MD
Published: Friday, Jun 01, 2012

Michael Rotkowitz, MD, medical oncologist, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses the side effects associated with the combination of dabrafenib and trametinib, two investigational agents for advanced melanoma.

The current standard of care for advanced melanoma with a BRAF mutation is the targeted agent vemurafenib. Rotkowitz explains that most patients taking this agent will experience some form of side effect. However, he remains optimistic that the investigational combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib will avoid many of these side effects.

Data from the phase I/II study investigating the combination suggests that the occurrence of side effects such as squamous cell carcinoma and other benign tumors was less common than in vemurafenib alone, while demonstrating a similar survival benefit.

<<< View more from the 2012 ASCO Conference

Michael Rotkowitz, MD, medical oncologist, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses the side effects associated with the combination of dabrafenib and trametinib, two investigational agents for advanced melanoma.

The current standard of care for advanced melanoma with a BRAF mutation is the targeted agent vemurafenib. Rotkowitz explains that most patients taking this agent will experience some form of side effect. However, he remains optimistic that the investigational combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib will avoid many of these side effects.

Data from the phase I/II study investigating the combination suggests that the occurrence of side effects such as squamous cell carcinoma and other benign tumors was less common than in vemurafenib alone, while demonstrating a similar survival benefit.

<<< View more from the 2012 ASCO Conference


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Post-Transplant ObstaclesMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x